MOUNTAIN VIEW, Calif., July 29, 2010 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) today announced that it will report financial results for the second quarter ended June 30, 2010 after the NASDAQ Market closes on Monday, August 2, 2010.

The company will discuss financial results and provide a business update through a conference call and an audio webcast at 1:30pm PT on the same day.

Date: August 2, 2010

Time: 1:30 PM PT

Listen via Internet:

Schedule this webcast into MS-Outlook calendar (click open when prompted):

Toll-free:   (877) 359-2916

International:   (224) 357-2386

A webcast replay will be available on the VIVUS web site for 30 days.

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit
CONTACT:  VIVUS, Inc.          Timothy E. Morris, Chief Financial Officer          650-934-5200          The Trout Group          Investor Relations:          Brian Korb          646-378-2923          Pure Communications, Inc.          Media Relations:          Dan Budwick          973-271-6085